The presence of multiple NS 5A RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS 5A inhibitor‐naïve patients with chronic HCV genotype 1b infection in a real‐world cohort

2018 ◽  
Vol 25 (5) ◽  
pp. 535-542 ◽  
Author(s):  
R. Kozuka ◽  
H. Hai ◽  
H. Motoyama ◽  
A. Hagihara ◽  
H. Fujii ◽  
...  
Keyword(s):  
Real World ◽  
Hcv Genotype ◽  
Genotype 1B ◽  
Chronic Hcv

scholarly journals Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1B

2021 ◽  
Vol 24 (1) ◽  
pp. 44-50
Author(s):  
Mircea Manuc ◽  
◽  
Carmen Monica Preda ◽  
Laura Iliescu ◽  
Doina Istratescu ◽  
...  
Keyword(s):  
Adverse Events ◽  
Real World ◽  
Drop Out ◽  
Real World Data ◽  
Serious Adverse Events ◽  
Intention To Treat ◽  
Genotype 1B ◽  
Male Patients ◽  
Severe Adverse Events ◽  
Chronic Hcv

Background and aims. For the 8-week OPrD regimen, real world data are insufficient. This study aims to compare the efficacy of the two types of regimens (12-week versus 8-week) in a real world cohort of patients with genotype 1b. Material and methods. We analysed a multicentric retrospective cohort enrolling 1436 patients who started HCV therapy in 2018-2019. Liver fibrosis was staged in all subjects by Fibromax. Efficacy was assessed by the percentage of patients achieving SVR 12 weeks post-treatment (SVR12). Results. Out of the 1436 analysed patients, 112 received 8 weeks therapy and 1324 received 12 weeks. In this cohort the proportion of male patients was 25.2%, the median age 61 years, 28.2% were interferon pre-treated, and the rate of co-morbidities was 47%. 42% of the subjects had F2 fibrosis, 29% F1 fibrosis, 16% F3 and 12% F4. The SVR rate was comparable in both groups of patients (97% in those treated with OPrD 12 weeks vs 96.4% in those that received OPrD 8 weeks) (by intention-to-treat). In the 12 weeks arm, the drop-out rate was 0.8% and the rate of severe adverse events was 1%, while in the arm of 8 weeks therapy there were no severe adverse events reported and no drop-out (p = 0.25). The only predictive factor for non-response in both treatment arms was the male sex. Conclusions. OPrD 8 weeks proved to be highly efficient in our patients with a 96.4% SVR. No serious adverse events and no drop out were reported.

scholarly journals Genotype-specific versus pangenotypic regimens in patients infected with HCV genotype 1b in real-world settings

2021 ◽  
Author(s):  
Paweł Pabjan ◽  
Michał Brzdęk ◽  
Magdalena Chrapek ◽  
Kacper Dziedzic ◽  
Piotr M. Stępień ◽  
...  
Keyword(s):  
Real World ◽  
Hcv Genotype ◽  
Genotype 1B

Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

2018 ◽  
Vol 17 (3) ◽  
pp. 235-241 ◽  
Author(s):  
Esther Chamorro-de-Vega ◽  
Alvaro Gimenez-Manzorro ◽  
Carmen-Guadalupe Rodriguez-Gonzalez ◽  
Vicente Escudero-Vilaplana ◽  
Ana De Lorenzo-Pinto ◽  
...  
Keyword(s):  
Cohort Study ◽  
Real World ◽  
Hcv Genotype ◽  
Compensated Cirrhosis ◽  
Genotype 1B

scholarly journals Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hepatology ◽  
2014 ◽  
Vol 59 (6) ◽  
pp. 2083-2091 ◽  
Author(s):  
Hiromitsu Kumada ◽  
Yoshiyuki Suzuki ◽  
Kenji Ikeda ◽  
Joji Toyota ◽  
Yoshiyasu Karino ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 1B ◽  
Chronic Hcv

scholarly journals Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients

2017 ◽  
Vol 28 (2) ◽  
pp. 80-86 ◽  
Author(s):  
Daniel Palenzuela Gardón ◽  
Isabel Alicia Guillen ◽  
Julio R. Fernández ◽  
Hamlet Camacho ◽  
Zurina Cinza Estevez ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 1B ◽  
Chronic Hcv

HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b

2015 ◽  
Vol 9 (3) ◽  
pp. 424-430 ◽  
Author(s):  
Yosuke Hirotsu ◽  
Tatsuo Kanda ◽  
Hiroshi Matsumura ◽  
Mitsuhiko Moriyama ◽  
Osamu Yokosuka ◽  
...  
Keyword(s):  
Real World ◽  
Japanese Patients ◽  
Hcv Genotype ◽  
Genotype 1B
Sign in / Sign up

Export Citation Format

Share Document